Résidu tumoral et réponse au traitement

Membres

Fabien Reyal, MD, PhD

Reyal

Fabien Reyal Chef d'équipe Equipe Reyal Retour à la liste

Publications clés

Année de publication : 2020

Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S,Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E. (2020 Feb 19)

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Science Translational MedicineScience Translational Medicine : DOI : 10.1126/scitranslmed.aax2625

Année de publication : 2015

Bonsang-Kitzis H1, Sadacca B2, Hamy-Petit AS3, Moarii M4, Pinheiro A3, Laurent C3, Reyal F1. (2019 Jun 24)

Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.

Oncoimmunology : 5 : 1061176 : DOI : 10.1080/2162402X.2015.1061176
Cristina Ghirelli, Fabien Reyal, Marine Jeanmougin, Raphaël Zollinger, Philémon Sirven, Paula Michea, Christophe Caux, Nathalie Bendriss-Vermare, Marie-Hélène Donnadieu, Martial Caly, Virginie Fourchotte, Anne Vincent-Salomon, Brigitte Sigal-Zafrani, Xavier Sastre-Garau, Vassili Soumelis (2015 May 16)

Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes.

Cancer research : 2775-87 : DOI : 10.1158/0008-5472.CAN-14-2386

Année de publication : 2012

Angélique Bobrie, Sophie Krumeich, Fabien Reyal, Chiara Recchi, Luis F Moita, Miguel C Seabra, Matias Ostrowski, Clotilde Théry (2012 Aug 3)

Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression.

Cancer research : 4920-30 : DOI : 10.1158/0008-5472.CAN-12-0925